Therapeutic Insulin Analogue Concentrations at Infusion Sites Enhanced the Pro-Inflammatory Response and Apoptosis in an In Vitro Macrophage-Material Interaction Model

Overview

Journal ACS Pharmacol Transl Sci

Publisher American Chemical Society

Specialty Biochemistry

Date 2024 Aug 19

PMID 39156741

Authors

Yuxi Zhang

Luke Kuo

Kimberly A Woodhouse

Lindsay E Fitzpatrick

Affiliations

Soon will be listed here.

Abstract

Continuous subcutaneous insulin infusion for Type 1 diabetes relies upon insulin infusion sets (IIS) to reliably deliver insulin to a subcutaneous depot, where it is absorbed into systemic circulation. However, IIS are plagued by short wear times and high failure rates, due in part to inconsistent insulin absorption that can arise over time. While emerging evidence suggests that the local inflammatory response to the IIS cannula may impact both wear times and unreliable insulin adsorption, the mechanisms are poorly understood. Here, we investigated the effects of local infused insulin concentrations on the biomaterial host response to better understand the underlying factors that limit the IIS performance. We first modeled the insulin concentration for a constant basal infusion rate to select a relevant insulin concentration range of 0.1-10 U/mL within the infusion site. We then examined the influence of a commercial insulin analogue (Humulin-N) using an in vitro macrophage-material model, which uses adsorbed fibroblast lysate (containing damage-associated molecular patterns) to activate macrophages and recapitulates macrophage responses on implanted biomaterials. RAW-Blue macrophages cultured on lysate-adsorbed surfaces had increased nuclear factor-κB (NF-κB) and activating protein 1 (AP-1) activity and intracellular reactive oxygen species (ROS) accumulation compared to control surfaces. Humulin-N concentration (0.5-10 U/mL) enhanced the NF-κB/AP-1 activity and ROS accumulation in macrophages on lysate-adsorbed surfaces. However, Humulin-N had no effect on NF-κB/AP-1 or ROS in the absence of the inflammatory stimulus. Additionally, high insulin concentrations arising from therapeutic doses induced macrophage apoptosis with and without adsorbed lysate. This study contributes to emerging evidence that infused insulin affects the tissue response to IIS.

References

Kaushal A, Zhang Y, Ballantyne L, Fitzpatrick L . The extended effect of adsorbed damage-associated molecular patterns and Toll-like receptor 2 signaling on macrophage-material interactions. Front Bioeng Biotechnol. 2022; 10:959512. PMC: 9458975. DOI: 10.3389/fbioe.2022.959512. View

Linkeschova R, Raoul M, Bott U, Berger M, Spraul M . Less severe hypoglycaemia, better metabolic control, and improved quality of life in Type 1 diabetes mellitus with continuous subcutaneous insulin infusion (CSII) therapy; an observational study of 100 consecutive patients followed for a mean of 2.... Diabet Med. 2002; 19(9):746-51. DOI: 10.1046/j.1464-5491.2002.00713.x. View

Chen H, Agrawal D, Thankam F . Biomaterials-Driven Sterile Inflammation. Tissue Eng Part B Rev. 2020; 28(1):22-34. PMC: 8892963. DOI: 10.1089/ten.TEB.2020.0253. View

Mulka A, Lewis B, Mao L, Sharafieh R, Kesserwan S, Wu R . Phenolic Preservative Removal from Commercial Insulin Formulations Reduces Tissue Inflammation while Maintaining Euglycemia. ACS Pharmacol Transl Sci. 2021; 4(3):1161-1174. PMC: 8205237. DOI: 10.1021/acsptsci.1c00047. View

Anderson J, Rodriguez A, Chang D . Foreign body reaction to biomaterials. Semin Immunol. 2007; 20(2):86-100. PMC: 2327202. DOI: 10.1016/j.smim.2007.11.004. View

Wilcox G . Insulin and insulin resistance. Clin Biochem Rev. 2005; 26(2):19-39. PMC: 1204764. View

Hoogma R, Hammond P, Gomis R, Kerr D, Bruttomesso D, Bouter K . Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH-based multiple daily insulin injections (MDI) on glycaemic control and quality of life: results of the 5-nations trial. Diabet Med. 2006; 23(2):141-7. DOI: 10.1111/j.1464-5491.2005.01738.x. View

Zhang A, Wellberg E, Kopp J, Johnson J . Hyperinsulinemia in Obesity, Inflammation, and Cancer. Diabetes Metab J. 2021; 45(3):285-311. PMC: 8164941. DOI: 10.4093/dmj.2020.0250. View

Senstius J, Poulsen C, Hvass A . Comparison of in vitro stability for insulin aspart and insulin glulisine during simulated use in insulin pumps. Diabetes Technol Ther. 2007; 9(6):517-21. DOI: 10.1089/dia.2007.0233. View

10.

Ieronymaki E, Daskalaki M, Lyroni K, Tsatsanis C . Insulin Signaling and Insulin Resistance Facilitate Trained Immunity in Macrophages Through Metabolic and Epigenetic Changes. Front Immunol. 2019; 10:1330. PMC: 6581697. DOI: 10.3389/fimmu.2019.01330. View

11.

Tarin C, Teufel E, Pico J, Bondia J, Pfleiderer H . Comprehensive pharmacokinetic model of insulin Glargine and other insulin formulations. IEEE Trans Biomed Eng. 2005; 52(12):1994-2005. DOI: 10.1109/TBME.2005.857681. View

12.

Pickup J, Sutton A . Severe hypoglycaemia and glycaemic control in Type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion. Diabet Med. 2008; 25(7):765-74. DOI: 10.1111/j.1464-5491.2008.02486.x. View

13.

Clotman K, Janssens K, Specenier P, Weets I, De Block C . Programmed Cell Death-1 Inhibitor-Induced Type 1 Diabetes Mellitus. J Clin Endocrinol Metab. 2018; 103(9):3144-3154. DOI: 10.1210/jc.2018-00728. View

14.

Weichhart T, Hengstschlager M, Linke M . Regulation of innate immune cell function by mTOR. Nat Rev Immunol. 2015; 15(10):599-614. PMC: 6095456. DOI: 10.1038/nri3901. View

15.

Heinemann L, Fleming G, Petrie J, Holl R, Bergenstal R, Peters A . Insulin pump risks and benefits: a clinical appraisal of pump safety standards, adverse event reporting and research needs. A joint statement of the European Association for the Study of Diabetes and the American Diabetes Association Diabetes.... Diabetologia. 2015; 58(5):862-70. DOI: 10.1007/s00125-015-3513-z. View

16.

McKiel L, Fitzpatrick L . Toll-like Receptor 2-Dependent NF-κB/AP-1 Activation by Damage-Associated Molecular Patterns Adsorbed on Polymeric Surfaces. ACS Biomater Sci Eng. 2021; 4(11):3792-3801. DOI: 10.1021/acsbiomaterials.8b00613. View

17.

Doloff J, Ma M, Sadraei A, Tam H, Farah S, Hollister-Lock J . Identification of a humanized mouse model for functional testing of immune-mediated biomaterial foreign body response. Sci Adv. 2023; 9(24):eade9488. PMC: 10275594. DOI: 10.1126/sciadv.ade9488. View

18.

Tsarkova P, Chakarova N, Dimova R, Grozeva G, Todorova A, Serdarova M . CSII is related to more stable glycemia in adults with type 1 diabetes. Endocrine. 2021; 75(3):776-780. DOI: 10.1007/s12020-021-02913-9. View

19.

Little S, Leelarathna L, Walkinshaw E, Tan H, Chapple O, Lubina-Solomon A . Recovery of hypoglycemia awareness in long-standing type 1 diabetes: a multicenter 2 × 2 factorial randomized controlled trial comparing insulin pump with multiple daily injections and continuous with conventional glucose self-monitoring.... Diabetes Care. 2014; 37(8):2114-22. DOI: 10.2337/dc14-0030. View

20.

Pedersen D, Guilherme A, Danai L, Heyda L, Matevossian A, Cohen J . A major role of insulin in promoting obesity-associated adipose tissue inflammation. Mol Metab. 2015; 4(7):507-18. PMC: 4481426. DOI: 10.1016/j.molmet.2015.04.003. View